MPR Weekly Dose Podcast #123
Pharmacists now allowed to prescribe Paxlovid; new dosing recommendations for Evusheld; abuse-deterrent opioid analgesic; Priority Review for early Alzheimer disease treatment; morphine tablets recalled.
Alzheimer Disease and Dementia
MPR Weekly Dose Podcast #121
Skyrizi gains new approval; the USPSTF make recommendations on multivitamin use to prevent CVD and cancer; an FDA Panel vote on pimavanserin efficacy for treating hallucinations associated with Alzheimer disease psychosis; Phexxi analysed in over 1000 patients; and Vaxneuvance approved for some pediatrics.
FDA Panel Votes on Pimavanserin for Alzheimer Disease Psychosis
Although not bound by the committee’s recommendations, the Agency does take them into consideration when making decisions on approval.
Crenezumab Misses Endpoints in Autosomal Dominant Alzheimer Disease Trial
Crenezumab is an investigational monoclonal antibody designed to neutralize neurotoxic oligomers, a form of beta-amyloid.
May 2022: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
One in 3 Alzheimer, Dementia Cases Tied to Modifiable Risk Factors
Risk factors differ based on sex and race and ethnicity
FDA Greenlights In Vitro Diagnostic Test to Assess for Alzheimer Disease
The Lumipulse G β-Amyloid Ratio (1-42/1-40) test is intended to be used as an aid in adults 55 years of age and older presenting with cognitive impairment who are being evaluated for Alzheimer disease and other causes of cognitive decline.
Immunotherapeutic Vaccine Candidate Fast Tracked for Alzheimer Disease
UB-311 is an immunotherapeutic vaccine candidate that targets toxic forms of aggregated amyloid beta in the brain.
Subcutaneous Anti-Amyloid Beta Antibody Fast Tracked for Alzheimer Disease
In preclinical studies, PRX012 has been shown to bind to beta amyloid plaques and oligomers with high affinity.
DMARDs Not Linked to Alzheimer Risk for Seniors With RA
No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept
